EU Expansion and Combination Therapies Will Drive Future Opportunity

Key Takeaways

• Decades of patent protection and growing disease prevalence position Rezdiffra for sustained revenue growth, market expansion, and pricing power.
  
• International launches, pipeline diversification, and solid financial resources reduce risk and support expansion into new markets and indications.
  
• Dependence on a single drug, rising competition, reimbursement challenges, expansion risks, and escalating costs threaten Madrigal's margins, growth prospects, and earnings stability.

Catalysts

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

• The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.
  
• The increasing global prevalence of advanced metabolic and liver diseases, driven by aging populations and lifestyle trends, is expanding the addressable market for Rezdiffra; the company's early-stage penetration (7% of diagnosed U.S. MASH patients) leaves significant room for future patient growth and recurring revenues.
  
• Upcoming international expansion, beginning with the imminent launch in Germany and broader EU approval, positions the company to tap into new, underpenetrated markets with a sizeable diagnosed MASH population and limited competition, driving incremental revenue growth.
  
• Pipeline development, including the combination of Rezdiffra with a newly in-licensed oral GLP-1 agent, leverages advances in targeted metabolic therapies and positions Madrigal for future indication expansion and combination treatment adoption-supporting long-term revenue diversification and lifecycle management.
  
• The company's strong cash reserves and favorable non-dilutive financing provide ample resources for business development, clinical advancement, and scaling operations, reducing financial risk and supporting investment in initiatives likely to boost future net income and earnings stability.

Madrigal Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Madrigal Pharmaceuticals's revenue will grow by 42.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from -27.3% today to 28.8% in 3 years time.
• Analysts expect earnings to reach $935.6 million (and earnings per share of $30.16) by about June 2029, up from -$309.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.6 billion in earnings, and the most bearish expecting $611.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.8x on those 2029 earnings, up from -37.3x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
• Analysts expect the number of shares outstanding to grow by 3.44% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.16%, as per the Simply Wall St company report.

Risks

• Heavy reliance on a single lead asset (Rezdiffra/resmetirom) exposes Madrigal to substantial risk if future clinical data (e.g., in F4c population) disappoint or if unforeseen safety/efficacy issues emerge, potentially resulting in significant revenue and earnings volatility.
  
• Intensifying competition-including upcoming launches of GLP-1 class drugs and pipeline therapies from large-cap pharma-could erode Madrigal's first-mover advantage, put downward pressure on market share, and force pricing or rebating concessions, impacting both top-line growth and net margins.
  
• Continued healthcare cost containment and reimbursement scrutiny-especially as payer contracting ramps up in the second half of 2025 and beyond-may drive gross to net discounts higher over time, limiting long-term pricing power and compressing future gross and net margins.
  
• International expansion carries operational and reimbursement risks, especially in complex European markets where access, pricing, and adoption curves may be slower or flatter than in the U.S., delaying or diminishing expected revenue contributions from ex-U.S. launches.
  
• High and rising SG&A and R&D expenses-particularly as Madrigal builds its pipeline and business development ambitions-could pressure operating margins and require further external financing, raising the risk of future shareholder dilution or elevated interest expense, negatively affecting long-term earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $678.71 for Madrigal Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $964.0, and the most bearish reporting a price target of just $542.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.2 billion, earnings will come to $935.6 million, and it would be trading on a PE ratio of 22.8x, assuming you use a discount rate of 7.2%.
• Given the current share price of $501.19, the analyst price target of $678.71 is 26.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.